View Exam | PowerPak

1. Which of the following statements about extensive-stage small cell lung cancer (ES-SCLC) is CORRECT?

A. Many patients initially respond to first-line chemotherapy or radiation therapy B. Few patients initially respond to first-line chemotherapy or radiation therapy C. The 1-year survival rate with first-line chemotherapy is greater than 60% D. ES-SCLC often bears numerous oncogenic mutations that may respond to targeted therapies E. Unsure

2. The primary risk factor for SCLC is:

A. Genetic predisposition B. Cigarette smoking C. Environmental exposure D. Prior chest radiation E. Unsure

3. Which of the following is TRUE about brain or central nervous system (CNS) metastases in patients with advanced SCLC?

A. They cannot be detected at diagnosis but may develop in up to 15% of patients during disease course B. They are detected in 60% of patients at diagnosis and can develop in up to 90% of patients during disease course C. They are detected in 10% to 25% of patients at diagnosis and can subsequently develop in an additional 40% to 50% D. They rarely occur in this patient population E. Unsure

4. Immune checkpoint inhibitors (ICIs) are increasingly used for treatment of advanced SCLC. Which one of the following statements is TRUE about ICIs in SCLC treatment?

A. They should be used only after confirming high-level PD-L1 expression in tumor tissue B. They are only effective in patients with a high tumor mutation burden C. Assessment of PD-L1 tumor expression is not required for their use in SCLC D. They are approved for use in patients with PD-L1 expression on at least 5% of tumor cells E. Unsure

5. Lurbinectedin is currently approved for treatment of patients with:

A. Previously untreated metastatic SCLC with high PD-L1 expression B. Locally advanced SCLC resistant to topotecan C. Advanced SCLC with a high Ki-67 proliferative index D. Metastatic SCLC with disease progression on or after platinum-based chemotherapy E. Unsure

6. Anlotinib has demonstrated efficacy in the treatment of SCLC, either as monotherapy or combined with platinum/etoposide. Anlotinib is best classified as a(n):

A. Immune checkpoint inhibitor B. Anti-TIGIT monoclonal antibody C. Poly (ADP-ribose) polymerase (PARP) inhibitor D. Antiangiogenic tyrosine kinase inhibitor E. Unsure

7. In the IMpower133 Phase 3 trial in patients with ES-SCLC who had not previously received systemic therapy, addition of atezolizumab to carboplatin/etoposide chemotherapy resulted in:

A. A significant increase in median PFS and median mOS compared to the control arm B. No significant improvement in mPFS or mOS compared to the control arm C. A significant increase in mPFS or mOS only in those with PD-L1 expression ≥ 50% D. Noninferiority compared to survival in the control arm E. Unsure

8. In which of the following SCLC trials did NOT enroll patients with brain metastases?

A. IMpower133 trial of atezolizumab B. CASPIAN trial of durvalumab C. Phase 2 trial of lurbinectedin D. KEYNOTE-604 trial of pembrolizumab E. Unsure

9. ER is a 68-year-old male diagnosed with ES-SCLC (ECOG performance status of 1) and no detectable brain metastases. He received first-line therapy with carboplatin AUC 5 mg/mL/min on day 1, etoposide 100 mg/m2 on days 1-3, and durvalumab 1500 mg on day 1 IV every 3 weeks, followed by durvalumab 1500 mg IV every 4 weeks as maintenance therapy. ER tolerated his chemoimmunotherapy well with minimal side effects. Following an initial response, after 8 months he experienced disease progression. He still has an ECOG performance status of 1 and his labs remain within normal range. According to NCCN guidelines, preferred second-line treatment for ER would be:

A. Topotecan B. Lurbinectedin C. Re-treatment with carboplatin/etoposide D. Supportive care only E. Unsure

10. AZ is a 63-year-old female with ES-SCLC (ECOG performance status of 1) and no brain metastases who received first-line therapy with carboplatin AUC 5 mg/mL/min on day 1, etoposide 100 mg/m2 on days 1-3, and atezolizumab 1200 mg on day 1 IV every 3 weeks, followed by maintenance atezolizumab 1680 mg IV every 4 weeks. Despite a good initial response, she relapsed 3 months later. She still has an ECOG performance status of 1 and her labs remain within normal range. A reasonable second-line treatment option for AZ would be:

A. Carboplatin/etoposide at a higher dose B. Olaparib C. Lurbinectedin D. Supportive care only E. Unsure

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following statements about extensive-stage small cell lung cancer (ES-SCLC) is CORRECT?

2. The primary risk factor for SCLC is:

3. Which of the following is TRUE about brain or central nervous system (CNS) metastases in patients with advanced SCLC?

4. Immune checkpoint inhibitors (ICIs) are increasingly used for treatment of advanced SCLC. Which one of the following statements is TRUE about ICIs in SCLC treatment?

5. Lurbinectedin is currently approved for treatment of patients with:

6. Anlotinib has demonstrated efficacy in the treatment of SCLC, either as monotherapy or combined with platinum/etoposide. Anlotinib is best classified as a(n):

7. In the IMpower133 Phase 3 trial in patients with ES-SCLC who had not previously received systemic therapy, addition of atezolizumab to carboplatin/etoposide chemotherapy resulted in:

8. In which of the following SCLC trials did NOT enroll patients with brain metastases?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following statements about extensive-stage small cell lung cancer (ES-SCLC) is CORRECT?

2. The primary risk factor for SCLC is:

3. Which of the following is TRUE about brain or central nervous system (CNS) metastases in patients with advanced SCLC?

4. Immune checkpoint inhibitors (ICIs) are increasingly used for treatment of advanced SCLC. Which one of the following statements is TRUE about ICIs in SCLC treatment?

5. Lurbinectedin is currently approved for treatment of patients with:

6. Anlotinib has demonstrated efficacy in the treatment of SCLC, either as monotherapy or combined with platinum/etoposide. Anlotinib is best classified as a(n):

7. In the IMpower133 Phase 3 trial in patients with ES-SCLC who had not previously received systemic therapy, addition of atezolizumab to carboplatin/etoposide chemotherapy resulted in:

8. In which of the following SCLC trials did NOT enroll patients with brain metastases?

« Return to Activity

Customers who Purchased
this Activity also Purchased